Clinical Trial Update: A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535]) [Phase 1]

View source ↗

Summary

This Phase 1 pharmacokinetic study evaluated MK-8931 (verubecestat) in subjects with renal impairment after a single-dose administration to assess PK and potent…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Verubecestat (MK-8931)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED